Physician profile
Daniel Ivan Hernandez
NPI 1487615449
$1,639.94
in general payments reported to CMS, 2019-2025
25 companies · $164 in 2025
The $164 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $267 · 2021: $258 · 2022: $177 · 2023: $206 · 2024: $141 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $293.16 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $167.52 | 2019-2021 | |
| Novo Nordisk INC | $117.38 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $111.81 | 2019-2021 | |
| Myovant Sciences INC. | $110.63 | 2021-2022 | |
| Agile Therapeutics, INC. | $108.56 | 2022-2024 | Twirla |
| Organon LLC | $99.32 | 2021-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $84.09 | 2023-2024 | Myfembree |
| Hologic Sales and Service, LLC | $71.95 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $57.99 | 2019-2023 | |
| Sage Therapeutics, LLC | $57.60 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $52.04 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $39.79 | 2023-2025 | |
| Optumhealth Care Solutions, LLC | $37.85 | 2023 | Vivify Health Care Team Portal |
| Coopersurgical, INC. | $32.74 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $29.45 | 2020-2021 | |
| Avanos Medical | $27.63 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $22.78 | 2019 | |
| Abbott Laboratories | $20.55 | 2025 | Proclaim |
| Pfizer INC. | $19.72 | 2022 | |
| Convatec INC. | $18.09 | 2019 | |
| Lupin INC. | $16.18 | 2020 | |
| Allergan, INC. | $15.00 | 2019 | |
| Dysis Medical, INC. | $14.76 | 2020 | |
| Evofem Biosciences, INC. | $13.35 | 2023 | Phexxi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.